Concerns mounting over RMS Korea

Published: 2009-03-31 06:57:00

Updated: 2009-03-31 06:57:00

Korean Pharmaceutical firms and wholesalers need to assess the possible damage that foreign investment funds’ improper acquisition over local wholesaling firms would cause in the future and map out proper countermeasures, according to industry sources.

RMS Korea, a foreign investment firm, has...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK